The Galien Forum USA 2019

PANEL
5

Co-Chairs
Susan Desmond-Hellmann, MD, MPH
Chief Executive Officer
Bill & Melinda Gates Foundation
Prix Galien USA Committee Chair

Mike Rosenblatt, MD
Chief Medical Officer
Flagship Pioneering

Panelists
Albert Bourla, DVM, PhD
Chief Executive Officer
Pfizer

Jacqualyn Fouse, PhD
Chief Executive Officer
Agios

Christophe Weber, PharmD
Representative Director,
President & Chief Executive Officer
Takeda

Panel Intro

How will we be paying for medicine 10 years from now?


Co-Chair
Susan Desmond-Hellmann, MD, MPH
Chief Executive Officer
Bill & Melinda Gates Foundation
Prix Galien USA Committee Chair

Sue Desmond-Hellmann is CEO of the Bill & Melinda Gates Foundation. Trained as an oncologist, she spent 14 years at Genentech developing a number of breakthrough medicines, including two of the first gene-targeted therapies for cancer, Avastin and Herceptin. In November 2009, Forbes named her one of the world’s seven most “powerful innovators,” calling her “a hero to legions of cancer patients.” In her current role she champions precision public health – getting the right interventions, to the right populations, in the right places, to save lives. Previously, Sue was the first female chancellor of the University of California at San Francisco (UCSF), and the first recruited from the private sector. She is the recipient of numerous honors and awards and was listed among Fortune magazine’s “top 50 most powerful women in business” for seven years. In 2010, she was inducted into the American Academy of Arts and Sciences and elected to the Institute of Medicine. Sue is a director at Facebook Inc.


Mike_OhanaCo-Chair
Mike Rosenblatt, MD

Chief Medical Officer
Flagship Pioneering

Dr. Rosenblatt’s career has been in academia, pharma and biotech/venture. He is a physician—scientist. He now serves as Chief Medical Officer of Flagship Pioneering in Cambridge, MA, a firm that originates new biotech companies. Previously, he was Merck’s first Chief Medical Officer. He also served as Dean of Tufts University School of Medicine, and before that, Robert Ebert Professor of Molecular Medicine and George R. Minot Professor at Harvard Medical School. He served as President of Beth Israel Deaconess Medical Center and Director of the Harvard-MIT Division of health Sciences and Technology.

At Merck, he co-led development of alendronate (FOSAMAX) for osteoporosis. He received the Fuller Albright Award, the Vincent du Vigneaud Award, and the Chairman’s Award from Merck. Active in biotechnology, he was a founder of ProScript, which discovered bortezomib (Velcade) for multiple myeloma, and Radius, which developed abaloparatide (Tymlos) for osteoporosis. Currently, he is a member of the Harvard Medical School Board of Fellows, and the research advisory committees of Massachusetts General, Brigham and Women’s, and Boston Children’s hospitals. He graduated summa cum laude from Columbia, and received his M.D. magna cum laude from Harvard. Internship, residency, and endocrinology training were all at Massachusetts General hospital.


Albert Bourla WebAlbert Bourla, DVM, PhD
Chief Executive Officer
Pfizer

As CEO, Albert Bourla leads Pfizer in its purpose to deliver breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.

During his more than 25 years at Pfizer, Albert has held a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO, Albert served as the Pfizer’s Chief Operating Officer, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions. He began his Pfizer career in 1993 in the Animal Health Division.

Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction. He is a director on multiple boards: Pfizer, Inc., The Pfizer Foundation, PhRMA, The Partnership for New York City, and Catalyst. Additionally, Albert is a member of the Business Roundtable and the Business Council.


Jacqualyn Fouse, PhD
Chief Executive Officer
Agios

Jacqualyn Fouse, PhD, is CEO of Agios. Previously, she served as President and Chief Operating Officer of Celgene, where she had also been President of Global Hematology and Oncology and Senior Vice President and Chief Financial Officer. Before that, Dr. Fouse was Chief Financial Officer of Bunge Limited, a global agribusiness and food company, and prior to that was Senior Vice President, Chief Financial Officer, and Head of Corporate Strategy at Alcon Laboratories. She has also been Chief Financial Officer at Swissair Group and held a variety of senior finance positions at Nestlé S.A. Earlier in her career, Dr. Fouse worked at Celanese Chemical and LTV Aerospace and Defense. She is a member of the Board of Directors of Dick’s Sporting Goods and Incyte.


Christophe Weber, PharmD
Representative Director,
President & Chief Executive Officer
Takeda

Christophe Weber is President and Chief Executive Officer of Takeda Pharmaceutical Company Ltd. He joined Takeda in April 2014 as Chief Operating Officer, was named President and Representative Director in June 2014 and was subsequently appointed Chief Executive Officer in April 2015.

Weber has introduced key transformations within the global organization which focus on the underlying principles of patient- and customer-centricity, accountability and being as agile as possible for a global company. These critical changes will help secure a strong and sustainable future for Takeda.

Weber has held leadership roles across many different businesses and geographies. Prior to joining Takeda, Mr. Weber held positions of increasing responsibility at GlaxoSmithKline (GSK) including President & General Manager at GSK Vaccines, CEO of GSK Biologicals SA in Belgium, and member of the GSK global Corporate Executive Team. From 2008 to 2010, Weber served as Asia Pacific SVP and Regional Director at GSK Asia Pacific in Singapore.

Weber holds a doctorate in pharmacy and pharmacokinetics from the University of Lyon, France. There, he also earned master’s degrees in pharmaceutical marketing and in accounting and finance, as well as a bachelor’s degree in statistics.